Lw. Evans et al., DEVELOPMENT, VALIDATION AND APPLICATION OF A 2-SITE ENZYME-LINKED-IMMUNOSORBENT-ASSAY FOR ACTIVIN-AB, Journal of Endocrinology, 153(2), 1997, pp. 221-230
Monoclonal antibodies, specific for the beta A and beta B subunits of
activin, were used to develop a new two-site ELISA for activin-AB. The
assay had a detection limit of 0.19 ng/ml. High concentrations of act
ivin-AB were found in bovine, ovine and porcine follicular fluids (FF)
, with less in human FF (1310, 1730, 688 and 7 ng/ml respectively). Re
covery of spiked activin-AB standard from human, bovine and ovine FFs
and from homogenized human placental extracts averaged 91%, 115%, 115%
and 94% respectively. Within-plate coefficients of variation for diff
erent concentrations of activin-AB were between 1.3% and 2.67%. The be
tween-plate coefficient of variation was 5.5%. Crossreactivity experim
ents showed the high specificity of the assay for activin-AB, with inh
ibin-A, inhibin-B, follistatin, activin-A and activin-B all cross-reac
ting <0.2%. Incubation with high concentrations of follistatin (500 ng
/ml) prior to assay did not affect the recovery of activin-AB, Samples
of bovine, porcine, ovine and human FF gave dose responses parallel t
o that of the standard, as did bovine granulosa cell-conditioned media
. In human and porcine FF, levels of activin-A and activin-AB were sim
ilar whereas, in bovine and ovine FF, activin-A levels were approximat
ely threefold higher than activin-AB levels. As we have reported previ
ously for activin-A, nearly all of the endogenous activin-AB in bovine
FF was detected in the eluate from gel permeation chromatography with
an M-r of >700 000 indicating its association with higher molecular w
eight binding protein(s). By contrast, after denaturation, immunoreact
ive activin-AB was detected with an M-r of similar to 25 000 consisten
t with the complete dissociation from binding proteins, Activin-A was
detected in relatively high concentrations in human FF (similar to 5 n
g/ml), homogenized placental extracts (4.35-95.5 ng/g), sera from preg
nant women (>4 ng/ml) and amniotic fluid (3-13 ng/ml), and in much low
er concentrations in postmenopausal serum (500 pg/ml), normal cycle se
rum (100-200 pg/ml), serum from gonadotrophin-treated women (200 pg/ml
) and normal adult male serum (225 pg/ml). Activin-A was also found in
the culture media from explants of human amnion, chorion, maternal de
cidua and placenta. In marked contrast, activin-AB was undetectable (<
0.19ng/ml) in all of these samples with the exception of human FF (sim
ilar to 7 ng/ml). In conclusion, we have developed a sensitive and spe
cific ELISA to measure total (bound+free) activin-AB. Preliminary resu
lts show a more restricted distribution of this isoform compared with
activin-h. The presence of high levels ofboth activin-A and activin-AB
in FF suggests a function for both isoforms in the developing ovarian
follicle.